Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes

Abstract

The present invention provides a compound represented by the formula (II), a prodrug thereof, a pharmaceutically acceptable salt of the compound or the prodrug, a pharmaceutical agent and a pharmacologically composition each comprising the compound, and others. (II) wherein R, R, R and R is independently selected from a hydrogen atom, a C1-C6 alkyl group which may be substituted, a C7-C14 aralkyl group which may be substituted and -C(=O)Rx; Rx represents a C1-C6 alkyl group which may be substituted, an aryl group which may be substituted, a heteroaryl group which may be substituted, a C1-C6 alkoxy group which may be substituted, or -NReRf; Ar represents an aromatic carbon ring which may be substituted and which may be fused, or an aromatic heterocyclic ring; Q represents -(CH2)m-(L)p- or -(L)p-(CH2)m-; m represents an integer selected from 0 to 2; n represents an integer selected from 1 and 2; p represents an integer selected from 0 and 1; L represents -O-, -S- or -NR-; and A represents an aryl group which may be substituted or a heteroaryl group which may be substituted.

Description

technical field [0001] The present invention relates to sulfglucospiro derivatives, their drug prodrugs and their pharmacologically acceptable salts which can be used as medicine. The present invention is particularly concerned with the ability to inhibit Na + -Glucose co-transporter 2 (SGLT2), which can be used as insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), diabetes, diabetic complications, obesity, etc. caused by hyperglycemia Sulfatose spiro derivatives, prodrugs thereof, and salts thereof for use as prophylactic or therapeutic drugs for the disease. Background technique [0002] Diabetic patients are increasing in recent years due to Westernization of eating habits and long-term lack of exercise. In diabetic patients, decreased insulin secretion and decreased sensitivity to insulin due to chronic hyperglycemia can be observed, which further increase blood sugar levels, thereby exacerbating symptoms. Currently, biguan...

AI Technical Summary

Problems solved by technology

However, in the case of administering a prodrug, it is desired to properly metabolize it in or near the target organ and convert it into an active compound. achieve a stable effect

In addition, attempts have been made to convert the glycosidic bond of the compound into a carbon-carbon bond (see Patent Documents 4 to 21), and to convert the glucose moiety into 5-thioglucose (see Patent Documents 22 to 26), but there are no active In terms of drug properties and metabolic stability, it needs to be further improved

Images